Search results

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The longitudinal Monitoring the Future (MTF) Panel study extends the work of the cross-sectional MTF Main study by following a subsample of graduating seniors through the entire adult life course. The selected respondents are surveyed every two years from ages 19-30. Starting at age 35, respondents are surveyed every five years, at ages 35, 40, 45, 50, 55, and 60 (FZ surveys). The FZ surveys cover many of the same topics as the 12th grade and follow-up surveys and include additional questions on life events and health.

This study contains only the age 35 survey data for the MTF longitudinal panel study participants that have reached age 35 (FZ1) through the 2021 data collection.

NOTE: Users must also request the core panel data file: MTF: Base Year and Follow-Up Core Panel Data, Ages 18-30, 1976-2021 (ICPSR 39223) because demographic information (e.g. sex, race/ethnicity) for the participants of the age 35 survey is included in the core panel data file.

Researchers can merge the Age 35 (FZ1) study data file with other MTF follow-up data in this series. This includes:

• MTF: Base Year and Follow-Up Core Data, Ages 18-30, 1976-2021 (ICPSR 39223)
• MTF: Base Year and Follow-Up Form 1 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39282)
• MTF: Base Year and Follow-Up Form 2 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39325)
• MTF: Base Year and Follow-Up Form 3 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39389)
• MTF: Base Year and Follow-Up Form 4 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39326)
• MTF: Base Year and Follow-Up Form 5 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39283)
• MTF: Base Year and Follow-Up Form 6 Panel Data, Ages 18-30, 1989-2021 (ICPSR 39388)
• MTF: Age 40-45 Panel Data, 1998-2021 [Restricted-Use] (ICPSR 39767)
• Forthcoming: MTF Panel Data for Ages 50-55, and 60

In addition to questions about lifetime, annual, and 30-day substance use, the Age 35 (FZ1) survey also includes questions covering:

• Substance use and its consequences (alcohol, marijuana/cannabis, other illicit drugs, substance use disorder symptoms)
• Methods of marijuana/cannabis use
• Own attitudes and perceptions about substance use
• Living arrangements and household characteristics
• Dating, marriage, and significant relationships
• Parenthood and family
• Employment: experiences, income, financial security, satisfaction
• Leisure time
• Local and global concerns
• Political interest and preferences
• Happiness; satisfaction with life domains and self
• Psychosocial constructs: self-esteem, locus of control, loneliness, risk-taking, boredom
• Health symptoms, healthy behaviors, COVID-19

Please see the study documentation available on the MTF Panel series page for question-specific details, including content areas included in all survey forms.

HIGHLIGHTS of this update:

• Missing data coding has been changed/simplified in this release. Please see the User Guide for details.
• Panel analysis weights are now included in the data file instead of a stand-alone file. Please see the updated documentation for information.

Please be alert for variable coding differences between paper and web survey versions, especially for questions skipped based on answers to other questions. Note the following:

• The web-based version of the survey was introduced in 2020.
• Paper vs. Web coding differences will be most noticeable for the questions related to substance use, relationship/marital status, employment, and family composition.
• Users will need to explore their data using V35035 (89940:FZ PAPER OR WEB - RESPONSE) to look for and understand any coding differences.

Extensive work has been done to document the history and use of the MTF substance use disorder questions and criteria. Please see Substance use disorder criteria sums in the Monitoring the Future Panel Study (Occasional Paper No. 101)

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The longitudinal Monitoring the Future (MTF) Panel study extends the work of the cross-sectional MTF Main study by following a subsample of graduating seniors through the entire adult life course. The selected respondents are surveyed every two years from ages 19-30. Starting at age 35, respondents are surveyed every five years, at ages 35, 40, 45, 50, 55, and 60 (FZ surveys). The FZ surveys cover many of the same topics as the 12th grade and follow-up surveys and include additional questions on life events and health.

This study contains only the survey data for age 60 for the MTF longitudinal panel study participants that have reached age 60 (FZ6) through the 2021 data collection.

NOTE: Users must also request the core panel data file: MTF: Base Year and Follow-Up Core Panel Data, Ages 18-30, 1976-2021 (ICPSR 39223) because demographic information (e.g. sex, race/ethnicity) for the participants of the age 60 survey is included in the core panel data file.

Researchers can merge the Age 60 study data file with other MTF follow-up data in this series. This includes:

• MTF: Base Year and Follow-Up Core Data, Ages 18-30, 1976-2021 (ICPSR 39223)
• MTF: Base Year and Follow-Up Form 1 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39282)
• MTF: Base Year and Follow-Up Form 2 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39325)
• MTF: Base Year and Follow-Up Form 3 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39389)
• MTF: Base Year and Follow-Up Form 4 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39326)
• MTF: Base Year and Follow-Up Form 5 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39283)
• MTF: Base Year and Follow-Up Form 6 Panel Data, Ages 18-30, 1989-2021 (ICPSR 39388)
• MTF: Age 35 Panel Data, 1993-2021 [Restricted-Use] (ICPSR 39749)
• MTF: Age 40 and 45 Panel Data, 1998-2021 [Restricted-Use] (ICPSR 39767)
• MTF: Ages 50 and 55 Panel Data, 2008-2021 [Restricted-Use] (ICPSR 39804)

In addition to questions about lifetime, annual, and 30-day substance use, the Age 60 (FZ6) survey also includes questions covering:

• Substance use and its consequences (alcohol, marijuana/cannabis, other illicit drugs, substance use disorder symptoms)
• Methods of marijuana/cannabis use
• Own attitudes and perceptions about substance use
• Living arrangements and household characteristics
• Dating, marriage, and significant relationships
• Family roles, obligations, burdens, emotional support
• Employment/retirement
• Income, financial security, satisfaction
• Community involvement, social issues
• Local and global concerns
• Political interest and preferences
• Happiness; satisfaction with life domains and self
• Psychosocial constructs: self-esteem, locus of control, loneliness, risk-taking, boredom
• Health symptoms and illnesses, healthy behaviors, COVID-19, medical treatments

Please see the study documentation available on the MTF Panel series page for question-specific details, including content areas included in all survey forms.

HIGHLIGHTS of this update:

• Missing data coding has been changed/simplified in this release. Please see the User Guide for details.
• Panel analysis weights are now included in the data file instead of a stand-alone file. Please see the updated documentation for information.

Please be alert for variable coding differences between paper and web survey versions, especially for questions skipped based on answers to other questions. Note the following:

• The web-based version of the survey was introduced in 2020.
• Paper vs. Web coding differences will be most noticeable for the questions related to substance use, relationship/marital status, employment, and family composition.
• Users will need to explore their data using V60035 (89940:FZ PAPER OR WEB - RESPONSE) to look for and understand any coding differences.

Extensive work has been done to document the history and use of the MTF substance use disorder questions and criteria. Please see Substance use disorder criteria sums in the Monitoring the Future Panel Study (Occasional Paper No. 101).

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The longitudinal Monitoring the Future (MTF) Panel study extends the work of the cross-sectional MTF Main study by following a subsample of graduating seniors through the entire adult life course. The selected respondents are surveyed every two years from ages 19-30. Starting at age 35, respondents are surveyed every five years, at ages 35, 40, 45, 50, 55, and 60 (FZ surveys). The FZ surveys cover many of the same topics as the 12th grade and follow-up surveys and include additional questions on life events and health.

This study contains only the survey data for ages 40 and 45 for the MTF longitudinal panel study participants that have reached age 40 (FZ2) and/or age 45 (FZ3) through the 2021 data collection.

NOTE: Users must also request the core panel data file: MTF: Base Year and Follow-Up Core Panel Data, Ages 18-30, 1976-2021 (ICPSR 39223) because demographic information (e.g. sex, race/ethnicity) for the participants of the age 40 and 45 surveys is included in the core panel data file.

Researchers can merge the Age 40-45 study data file with other MTF follow-up data in this series. This includes:

• MTF: Base Year and Follow-Up Core Data, Ages 18-30, 1976-2021 (ICPSR 39223)
• MTF: Base Year and Follow-Up Form 1 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39282)
• MTF: Base Year and Follow-Up Form 2 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39325)
• MTF: Base Year and Follow-Up Form 3 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39389)
• MTF: Base Year and Follow-Up Form 4 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39326)
• MTF: Base Year and Follow-Up Form 5 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39283)
• MTF: Base Year and Follow-Up Form 6 Panel Data, Ages 18-30, 1989-2021 (ICPSR 39388)
• MTF: Age 35 Panel Data, 1993-2021 [Restricted-Use] (ICPSR 39749)
• Forthcoming: MTF panel data for ages, 50-55, and 60

In addition to questions about lifetime, annual, and 30-day substance use, the Age 40 (FZ2) and Age 45 (FZ3) surveys also includes questions covering:

• Substance use and its consequences (alcohol, marijuana/cannabis, other illicit drugs, substance use disorder symptoms)
• Methods of marijuana/cannabis use
• Own attitudes and perceptions about substance use
• Living arrangements and household characteristics
• Dating, marriage, and significant relationships
• Family roles, obligations, burdens
• Employment: experiences, income, financial security, satisfaction
• Leisure time
• Local and global concerns
• Political interest and preferences
• Happiness; satisfaction with life domains and self
• Psychosocial constructs: self-esteem, locus of control, loneliness, risk-taking, boredom
• Health symptoms and illnesses, healthy behaviors, COVID-19

Please see the study documentation available on the MTF Panel series page for question-specific details, including content areas included in all survey forms.

HIGHLIGHTS of this update:

• Missing data coding has been changed/simplified in this release. Please see the User Guide for details.
• Panel analysis weights are now included in the data file instead of a stand-alone file. Please see the updated documentation for information.

Please be alert for variable coding differences between paper and web survey versions, especially for questions skipped based on answers to other questions. Note the following:

• The web-based version of the survey was introduced in 2020.
• Paper vs. Web coding differences will be most noticeable for the questions related to substance use, relationship/marital status, employment, and family composition.
• Users will need to explore their data using V40035/V45035 (89940:FZ PAPER OR WEB - RESPONSE) to look for and understand any coding differences.

Extensive work has been done to document the history and use of the MTF substance use disorder questions and criteria. Please see Substance use disorder criteria sums in the Monitoring the Future Panel Study (Occasional Paper No. 101)

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The longitudinal MTF Panel study extends the work of the cross-sectional MTF Main study by following a subsample of graduating seniors through the entire adult life course. The selected respondents are surveyed every two years from ages 19-30. Starting at age 35, respondents are surveyed every five years, at ages 35, 40, 45, 50, 55, and 60 (FZ surveys). The FZ surveys cover many of the same topics as the 12th grade and follow-up surveys and include additional questions on life events and health.

This study contains only the survey data for ages 50 and 55 for the MTF longitudinal panel study participants that have reached age 50 (FZ4) and/or age 55 (FZ5) through the 2021 data collection.

NOTE: Users must also request the core panel data file: MTF: Base Year and Follow-Up Core Panel Data, Ages 18-30, 1976-2021 (ICPSR 39223) because demographic information (e.g. sex, race/ethnicity) for the participants of the age 50 and 55 surveys is included in the core panel data file.

Researchers can merge the Age 50-55 study data file with other MTF follow-up data in this series. This includes:

• MTF: Base Year and Follow-Up Core Data, Ages 18-30, 1976-2021 (ICPSR 39223)
• MTF: Base Year and Follow-Up Form 1 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39282)
• MTF: Base Year and Follow-Up Form 2 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39325)
• MTF: Base Year and Follow-Up Form 3 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39389)
• MTF: Base Year and Follow-Up Form 4 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39326)
• MTF: Base Year and Follow-Up Form 5 Panel Data, Ages 18-30, 1976-2021 (ICPSR 39283)
• MTF: Base Year and Follow-Up Form 6 Panel Data, Ages 18-30, 1989-2021 (ICPSR 39388)
• MTF: Age 35 Panel Data, 1993-2021 [Restricted-Use] (ICPSR 39749)
• MTF: Ages 40 and 45 Panel Data, 1998-2021 [Restricted-Use] (ICPSR 39767)
• MTF: Age 60 Panel Data, 2018-2021 [Restricted-Use] (ICPSR 39779)

In addition to questions about lifetime, annual, and 30-day substance use, the Age 50 (FZ4) and Age 55 (FZ5) surveys also includes questions covering:

• Substance use and its consequences (alcohol, marijuana/cannabis, other illicit drugs, substance use disorder symptoms)
• Methods of marijuana/cannabis use
• Own attitudes and perceptions about substance use
• Living arrangements and household characteristics
• Dating, marriage, and significant relationships
• Family roles, obligations, burdens, emotional support
• Employment: income, financial security, satisfaction
• Community involvement, social issues
• Local and global concerns
• Political interest and preferences
• Happiness; satisfaction with life domains and self
• Psychosocial constructs: self-esteem, locus of control, loneliness, risk-taking, boredom
• Health symptoms and illnesses, healthy behaviors, COVID-19, medical treatments

Please see the study documentation available on the MTF Panel series page for question-specific details, including content areas included in all survey forms.

HIGHLIGHTS of this update:

• Missing data coding has been changed/simplified in this release. Please see the User Guide for details.
• Panel analysis weights are now included in the data file instead of a stand-alone file. Please see the updated documentation for information.

Please be alert for variable coding differences between paper and web survey versions, especially for questions skipped based on answers to other questions. Note the following:

• The web-based version of the survey was introduced in 2020.
• Paper vs. Web coding differences will be most noticeable for the questions related to substance use, relationship/marital status, employment, and family composition.
• Users will need to explore their data using V50035/V55035 (89940:FZ PAPER OR WEB - RESPONSE) to look for and understand any coding differences

Extensive work has been done to document the history and use of the MTF substance use disorder questions and criteria. Please see Substance use disorder criteria sums in the Monitoring the Future Panel Study (Occasional Paper No. 101).

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The MTF study consists of six different survey forms (five forms from 1976-1988). This study contains the data for Form 1 longitudinal panel participants. The MTF Form 1 Panel dataset includes data for the base year (BY) 12th grade surveys (modal age 18) and their young adult follow-up FU surveys (modal ages 19-30).

In addition to demographic-related questions and questions about lifetime, annual, and 30-day substance use that are included on all survey forms, Form 1 also includes questions covering:

• incidence of first use
• co-use of substances
• sources of obtaining substances
• perceived friends' use
• perceived availability of substances
• when, where, and with who substance use is occurring
• modes of substance use administration
• reasons for use or non-use
• own attitudes about substance use
• perceived risk of use
• substance use advertising
• sources of help and treatment
• free time and activities
• role of citizens in government, confidence in government
• voting and political activism
• attitudes towards discrimination
• satisfaction with life domains
• healthy behaviors
• physical health symptoms

Please see the study documentation available on the MTF Panel series page for question-specific details.

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The MTF study consists of six different survey forms (five forms from 1976-1988). This study contains the data for Form 2 longitudinal panel participants. The MTF Form 2 restricted panel dataset includes data for the base year (BY) 12th grade surveys (modal age 18) and their young adult follow-up FU surveys (modal ages 19-30).

In addition to demographic-related questions and questions about lifetime, annual, and 30-day substance use that are included on all survey forms, Form 2 also includes questions covering:

• Availability of drugs
• Confidence/trust in government
• Dating, marriage, and family
• Delinquency and victimization
• Expected future substance use
• Exposure to substance use
• Healthy behaviors, illness, COVID-19
• Leisure time activities, high school and post-high school
• Methods of marijuana use
• Military: plans for service, draft opinion
• Own attitudes and perceptions about substance use
• Perceived friends' substance use
• Perceived risk of substance use
• Psychosocial domains: boredom, loneliness, self-esteem, depressive affect, social support, self-efficacy, risk taking
• Satisfaction with life domains
• Sources of help and treatment for substance use
• Sources of marijuana
• Substance use initiation
• Vaping, including nicotine, marijuana, flavoring, sources
• Voting, political activism

NOTE: In 2020, school-based data collection was halted due to COVID-19. BY sample sizes were affected, and data for some questions on forms 2 and 3 were suppressed. The list of variables affected is found in the 2020 12th grade Codebook available through NAHDAP.

Please see the study documentation available on the MTF Panel series page for question-specific details , including content areas included in all survey forms.

NOTE: Researchers are encouraged to begin their work with the "core" data file, NAHDAP study 39223. Please see the User's Guide, IV. Working with the MTF Restricted Panel Data, for details.

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the MTF research team, describing the data collection and trends over time.

The MTF study consists of six different survey forms (forms 1-5 began in 1976; form 6 was added in 1989). This study contains the data for Form 3 longitudinal panel participants. The MTF Form 3 Panel dataset includes data for the base year (BY) 12th grade surveys (modal age 18) and their young adult follow-up FU surveys (modal ages 19-30).

In addition to demographic-related questions and questions about lifetime, annual, and 30-day substance use that are included on all survey forms, Form 3 also includes questions covering:

• Attitudes toward governmental policies and practices
• Dating and marriage: status, attitudes, expectations
• Ecological concerns, conservation of resources
• Happiness; satisfaction with life domains and self
• Health symptoms, healthy behaviors, COVID-19
• Leisure time, including computer, cell phone, and social media use
• Local and global concerns
• Methods of marijuana use
• Own attitudes and perceptions about substance use
• Parenthood: attitudes, expectations
• Perceived friends' substance use
• Perceived risk of substance use
• Race relations
• Substance use consequences (alcohol, marijuana/cannabis, other illicit drugs)

NOTE: In 2020, school-based data collection was halted due to COVID-19. BY sample sizes were affected, and data for some questions on forms 2 and 3 were suppressed. The list of variables affected is found in the 2020 12th grade Codebook available through NAHDAP.

Please see the study documentation available on the MTF Panel series page for question-specific details, including content areas included in all survey forms.

NOTE: Researchers are encouraged to begin their work with the "core" data file, NAHDAP study 39223. Please see the User's Guide, IV. Working with the MTF Restricted Panel Data, for details.

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The MTF study consists of six different survey forms (five forms from 1976-1988). This study contains the data for Form 4 longitudinal panel participants. The MTF Form 4 restricted panel dataset includes data for the base year (BY) 12th grade surveys (modal age 18) and their young adult follow-up FU surveys (modal ages 19-30).

In addition to demographic-related questions and questions about lifetime, annual, and 30-day substance use that are included on all survey forms, Form 4 also includes questions covering:

• Beer, Wine, hard liquor, wine coolers use
• Vaping sources
• Flavored, small, and large cigars
• Hookah, dissolvable tobacco, snus, and smokeless tobacco use
• Own attitudes and perceptions about substance use
• Perceived risk of substance use
• Perceived friends' substance use
• Perceived addictiveness of substances
• Legal Issues Regarding Drugs
• Delinquency, victimization, and feeling safe at school
• Vocational plans, aspirations, expectations
• Preferences regarding job characteristics
• Desirability of different working arrangements and settings
• Work ethic/success orientation
• Dating and marriage: status, attitudes, expectations
• Parenthood: attitudes, expectations
• Values surrounding marriage and family
• Personal materialism
• Ecological concerns, conservation of resources
• Attitudes toward governmental policies and practices
• Local and global concerns
• Voting behavior
• Attitudes toward the military as an institution and occupation
• Happiness; satisfaction with life domains and self

Please see the study documentation available on the MTF Panel series page for question-specific details.

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.

The MTF study consists of six different survey forms (five forms from 1976-1988). This study contains the data for Form 5 longitudinal panel participants. The MTF Form 5 restricted panel dataset includes data for the base year (BY) 12th grade surveys (modal age 18) and their young adult follow-up FU surveys (modal ages 19-30).

In addition to demographic-related questions and questions about lifetime, annual, and 30-day substance use that are included on all survey forms, Form 5 also includes questions covering:

• Non-prescription substance use, including Ritalin, Adderall, Oxycontin, Vicodin, fentanyl
• Energy drinks/shots
• Flavored alcohol, alcohol+caffeine
• Flavored small and large cigars
• Hookah
• dissolvable tobacco, snus, smokeless tobacco
• Synthetic marijuana use
• Incidence of first use
• Perceived risk of substance use
• Own and others' attitudes and perceptions about substance use
• Exposure to substance use
• Substance use problems
• Reasons for substance use, abstention or stopping use
• Perceived availability of substances
• Expected future substance use
• Sources of help and treatment for substance use
• Job-related substance use testing
• Methods of substance use
• Satisfaction with life domains
• Interpersonal relationships
• Parenthood: status, attitudes, expectations
• Dating, marriage, and family: status, values, attitudes, expectations, sex roles
• Military: plans for service, attitudes toward the military as an institution and occupation
• Working arrangements and settings
• Work ethic/success orientation
• Leisure time: extent, activities, and attitudes
• Community involvement
• Voting and political activism
• Political interest and preference
• Concern for others, locally and globally
• Conservation of resources, ecological concerns, mass transit
• Attitudes towards discrimination
• Expectations concerning societal change
• Reactions to personal and social change
• Personal materialism
• Delinquency and victimization
• Psychosocial domains: boredom, loneliness, self-esteem, depressive affect,social support, self-efficacy, risk taking
• Healthy behaviors, illness, COVID-19
• Post high school: status, plans, characteristics
• High school sport involvement, concussion
• Substance use education in high school

Please see the study documentation available on the MTF Panel series page for question-specific details, including content areas included in all survey forms.

More information about the MTF project can be accessed through the Monitoring the Future website. Annual reports are published by the research team, describing the data collection and trends over time.